{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:04:09Z","timestamp":1784055849667,"version":"3.55.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013104","name":"Scuola Internazionale Superiore di Studi Avanzati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00441-021-03573-x","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T07:02:48Z","timestamp":1641452568000},"page":"337-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic strategies for identifying small molecules against prion diseases"],"prefix":"10.1007","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0990-2532","authenticated-orcid":false,"given":"Elisa","family":"Uliassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Bolognesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-4393","authenticated-orcid":false,"given":"Giuseppe","family":"Legname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"3573_CR1","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1152\/physrev.00006.2009","volume":"89","author":"A Aguzzi","year":"2009","unstructured":"Aguzzi A, Calella AM (2009) Prions: protein aggregation and infectious diseases. Physiol Rev 89:1105\u20131152","journal-title":"Physiol Rev"},{"key":"3573_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev-pharmtox-010617-052745","volume":"58","author":"A Aguzzi","year":"2018","unstructured":"Aguzzi A, Lakkaraju AKK, Frontzek K (2018) Toward therapy of human prion diseases. Annu Rev Pharmacol Toxicol 58:331\u2013351","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3573_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-021-01162-1","volume":"9","author":"T Ali","year":"2021","unstructured":"Ali T, Hannaoui S, Nemani S, Tahir W, Zemlyankina I, Cherry P, Shim SY, Sim V, Schaetzl HM, Gilch S (2021) Oral administration of repurposed drug targeting Cyp46a1 increases survival times of prion infected mice. Acta Neuropathol Commun 9:58","journal-title":"Acta Neuropathol Commun"},{"key":"3573_CR4","doi-asserted-by":"publisher","first-page":"14882","DOI":"10.1523\/JNEUROSCI.0547-11.2011","volume":"31","author":"A Ayrolles-Torro","year":"2011","unstructured":"Ayrolles-Torro A, Imberdis T, Torrent J, Toupet K, Baskakov IV, Poncet-Montange G, Gr\u00e9goire C, Roquet-Baneres F, Lehmann S, Rognan D et al (2011) Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity. J Neurosci 31:14882\u201314892","journal-title":"J Neurosci"},{"key":"3573_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/pathogens7010027","volume":"7","author":"ML Barreca","year":"2018","unstructured":"Barreca ML, Iraci N, Biggi S, Cecchetti V, Biasini E (2018) Pharmacological agents targeting the cellular prion protein. Pathogens 7:27","journal-title":"Pathogens"},{"key":"3573_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1212\/WNL.42.1.149","volume":"42","author":"PE Bendheim","year":"1992","unstructured":"Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, Kascsak RJ, Cashman NR, Bolton DC (1992) Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 42:149\u2013156","journal-title":"Neurology"},{"key":"3573_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/01.wnf.0000134853.36429.0e","volume":"27","author":"J Benito-Le\u00f3n","year":"2004","unstructured":"Benito-Le\u00f3n J (2004) Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 27:201\u2013203","journal-title":"Clin Neuropharmacol"},{"key":"3573_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/cmdc.201000133","volume":"5","author":"ML Bolognesi","year":"2010","unstructured":"Bolognesi ML, Ai Tran HN, Staderini M, Monaco A, L\u00f3pez-Cobe\u00f1as A, Bongarzone S, Biarn\u00e9s X, L\u00f3pez-Alvarado P, Cabezas N, Caramelli M et al (2010) Discovery of a class of diketopiperazines as antiprion compounds. ChemMedChem 5:1324\u20131334","journal-title":"ChemMedChem"},{"key":"3573_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.4155\/fmc.15.79","volume":"7","author":"ML Bolognesi","year":"2015","unstructured":"Bolognesi ML, Bongarzone S, Aulic S, Ai Tran HN, Prati F, Carloni P, Legname G (2015) Rational approach to an antiprion compound with a multiple mechanism of action. Future Med Chem 7:2113\u20132120","journal-title":"Future Med Chem"},{"key":"3573_CR10","doi-asserted-by":"publisher","first-page":"7759","DOI":"10.1021\/acs.jmedchem.6b00151","volume":"59","author":"ML Bolognesi","year":"2016","unstructured":"Bolognesi ML, Gandini A, Prati F, Uliassi E (2016) From companion diagnostics to theranostics: a new avenue for Alzheimer\u2019s disease? J Med Chem 59:7759\u20137770","journal-title":"J Med Chem"},{"key":"3573_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2174\/138955706778742731","volume":"6","author":"ML Bolognesi","year":"2006","unstructured":"Bolognesi ML, Minarini A, Tumiatti V, Melchiorre C (2006) Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. Mini Rev Med Chem 6:1269\u20131274","journal-title":"Mini Rev Med Chem"},{"key":"3573_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4155\/fmc.14.56","volume":"6","author":"S Bongarzone","year":"2014","unstructured":"Bongarzone S, Staderini M, Bolognesi ML (2014) Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. Future Med Chem 6:1017\u20131029","journal-title":"Future Med Chem"},{"key":"3573_CR13","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.1021\/jm100882t","volume":"53","author":"S Bongarzone","year":"2010","unstructured":"Bongarzone S, Tran HN, Cavalli A, Roberti M, Carloni P, Legname G, Bolognesi ML (2010) Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem 53:8197\u20138201","journal-title":"J Med Chem"},{"key":"3573_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/cmdc.201100072","volume":"6","author":"S Bongarzone","year":"2011","unstructured":"Bongarzone S, Tran HN, Cavalli A, Roberti M, Rosini M, Carloni P, Legname G, Bolognesi ML (2011) Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. ChemMedChem 6:601\u2013605","journal-title":"ChemMedChem"},{"key":"3573_CR15","doi-asserted-by":"crossref","unstructured":"Booth SA (2017) What\u2019s next for genomics and prion diseases? Future Sci OA 3:FSO188","DOI":"10.4155\/fsoa-2017-0021"},{"key":"3573_CR16","doi-asserted-by":"publisher","first-page":"17338","DOI":"10.1021\/ja3063698","volume":"134","author":"K Cao","year":"2012","unstructured":"Cao K, Farahi M, Dakanali M, Chang WM, Sigurdson CJ, Theodorakis EA, Yang J (2012) Aminonaphthalene 2-cyanoacrylate (anca) probes fluorescently discriminate between amyloid-\u03b2 and prion plaques in brain. J Am Chem Soc 134:17338\u201317341","journal-title":"J Am Chem Soc"},{"key":"3573_CR17","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.1038\/s41598-018-25131-2","volume":"8","author":"KJ Cao","year":"2018","unstructured":"Cao KJ, Elbel KM, Cifelli JL, Cirera J, Sigurdson CJ, Paesani F, Theodorakis EA, Yang J (2018) Solvation-guided design of fluorescent probes for discrimination of amyloids. Sci Rep 8:6950","journal-title":"Sci Rep"},{"key":"3573_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fmolb.2017.00019","volume":"4","author":"AR Castle","year":"2017","unstructured":"Castle AR, Gill AC (2017) Physiological functions of the cellular prion protein. Front Mol Biosci 4:19","journal-title":"Front Mol Biosci"},{"key":"3573_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm7009364","volume":"51","author":"A Cavalli","year":"2008","unstructured":"Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347\u2013372","journal-title":"J Med Chem"},{"key":"3573_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14728222.2020.1782384","volume":"24","author":"A Colini Baldeschi","year":"2020","unstructured":"Colini Baldeschi A, Vanni S, Zattoni M, Legname G (2020) Novel regulators of PrPC expression as potential therapeutic targets in prion diseases.  Expert Opin Ther Targets 24:759\u2013776","journal-title":"Expert Opin Ther Targets"},{"key":"3573_CR21","doi-asserted-by":"publisher","first-page":"e00769","DOI":"10.1128\/JCM.00769-19","volume":"57","author":"A Connor","year":"2019","unstructured":"Connor A, Wang H, Appleby BS, Rhoads DD (2019) Clinical laboratory tests used to aid in diagnosis of human prion disease. J Clin Microbiol 57:e00769-e819","journal-title":"J Clin Microbiol"},{"key":"3573_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/07315724.2002.10719189","volume":"2","author":"JA Drisko","year":"2002","unstructured":"Drisko JA (2002) The use of antioxidants in transmissible spongiform encephalopathies: a case report. J Am Coll Nutr 2:22\u201325","journal-title":"J Am Coll Nutr"},{"key":"3573_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/mmi.13616","volume":"104","author":"Z Du","year":"2017","unstructured":"Du Z, Goncharoff DK, Cheng X, Li L (2017) Analysis of [swi. Mol Microbiol 104:105\u2013124","journal-title":"Mol Microbiol"},{"key":"3573_CR24","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.chembiol.2019.10.004","volume":"26","author":"Z Du","year":"2019","unstructured":"Du Z, Valtierra S, Cardona LR, Dunne SF, Luan CH, Li L (2019) Identifying anti-prion chemical compounds using a newly established yeast high-throughput screening system. Cell Chem Biol 26:1664\u20131680","journal-title":"Cell Chem Biol"},{"key":"3573_CR25","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1073\/pnas.162195499","volume":"99","author":"G Forloni","year":"2002","unstructured":"Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, Bertani I, Poli G, Caramelli M, Grazia Bruzzone M et al (2002) Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 99:10849\u201310854","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3573_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coph.2019.04.019","volume":"44","author":"G Forloni","year":"2019","unstructured":"Forloni G, Roiter I, Tagliavini F (2019) Clinical trials of prion disease therapeutics. Curr Opin Pharmacol 44:53\u201360","journal-title":"Curr Opin Pharmacol"},{"key":"3573_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1021\/jm200840c","volume":"55","author":"C Galdeano","year":"2012","unstructured":"Galdeano C, Viayna E, Sola I, Formosa X, Camps P, Badia A, Clos MV, Relat J, Ratia M, Bartolini M et al (2012) Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer\u2019s and prion diseases. J Med Chem 55:661\u2013669","journal-title":"J Med Chem"},{"key":"3573_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/bs.pmbts.2017.06.013","volume":"150","author":"A Gandini","year":"2017","unstructured":"Gandini A, Bolognesi ML (2017) Therapeutic approaches to prion diseases. Prog Mol Biol Transl Sci 150:433\u2013453","journal-title":"Prog Mol Biol Transl Sci"},{"key":"3573_CR29","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/cmdc.201100119","volume":"6","author":"M Geissen","year":"2011","unstructured":"Geissen M, Leidel F, Eiden M, Hirschberger T, Fast C, Bertsch U, Tavan P, Giese A, Kretzschmar H, Schatzl HM et al (2011) From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease. ChemMedChem 6:1928\u20131937","journal-title":"ChemMedChem"},{"key":"3573_CR30","doi-asserted-by":"publisher","first-page":"6919","DOI":"10.1021\/jm5001425","volume":"57","author":"S Ghaemmaghami","year":"2014","unstructured":"Ghaemmaghami S, Russo M, Renslo AR (2014) Successes and challenges in phenotype-based lead discovery for prion diseases. J Med Chem 57:6919\u20136929","journal-title":"J Med Chem"},{"key":"3573_CR31","doi-asserted-by":"publisher","first-page":"15253","DOI":"10.1038\/srep15253","volume":"5","author":"G Giachin","year":"2015","unstructured":"Giachin G, Mai PT, Tran TH, Salzano G, Benetti F, Migliorati V, Arcovito A, Della Longa S, Mancini G, D\u2019Angelo P et al (2015) The non-octarepeat copper binding site of the prion protein is a key regulator of prion conversion. Sci Rep 5:15253","journal-title":"Sci Rep"},{"key":"3573_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41594-020-0403-y","volume":"27","author":"C Glynn","year":"2020","unstructured":"Glynn C, Sawaya MR, Ge P, Gallagher-Jones M, Short CW, Bowman R, Apostol M, Zhou ZH, Eisenberg DS, Rodriguez JA (2020) Cryo-em structure of a human prion fibril with a hydrophobic, protease-resistant core. Nat Struct Mol Biol 27:417\u2013423","journal-title":"Nat Struct Mol Biol"},{"key":"3573_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, Azimi S, Pietrini V, Fabreguettes JR, Imperiale D et al (2014) Doxycycline in creutzfeldt-jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:150\u2013158","journal-title":"Lancet Neurol"},{"key":"3573_CR34","doi-asserted-by":"publisher","first-page":"14944","DOI":"10.1038\/srep14944","volume":"5","author":"JW Hyeon","year":"2015","unstructured":"Hyeon JW, Choi J, Kim SY, Govindaraj RG, Jam Hwang K, Lee YS, An SS, Lee MK, Joung JY, No KT et al (2015) Discovery of novel anti-prion compounds using in silico and in vitro approaches. Sci Rep 5:14944","journal-title":"Sci Rep"},{"key":"3573_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13024-016-0074-7","volume":"11","author":"T Imberdis","year":"2016","unstructured":"Imberdis T, Ayrolles-Torro A, Duarte Rodrigues A, Torrent J, Alvarez-Martinez MT, Kovacs GG, Verdier JM, Robitzer M, Perrier V (2016a) A fluorescent oligothiophene-bis-triazine ligand interacts with PRP fibrils and detects sds-resistant oligomers in human prion diseases. Mol Neurodegener 11:11","journal-title":"Mol Neurodegener"},{"key":"3573_CR36","doi-asserted-by":"publisher","first-page":"26164","DOI":"10.1074\/jbc.M116.745612","volume":"291","author":"T Imberdis","year":"2016","unstructured":"Imberdis T, Heeres JT, Yueh H, Fang C, Zhen J, Rich CB, Glicksman M, Beeler AB, Harris DA (2016b) Identification of anti-prion compounds using a novel cellular assay. J Biol Chem 291:26164\u201326176","journal-title":"J Biol Chem"},{"key":"3573_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ebiom.2016.06.010","volume":"9","author":"D Ishibashi","year":"2016","unstructured":"Ishibashi D, Nakagaki T, Ishikawa T, Atarashi R, Watanabe K, Cruz FA, Hamada T, Nishida N (2016) Structure-based drug discovery for prion disease using a novel binding simulation. EBioMedicine 9:238\u2013249","journal-title":"EBioMedicine"},{"key":"3573_CR38","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/jcc.21265","volume":"30","author":"T Ishikawa","year":"2009","unstructured":"Ishikawa T, Ishikura T, Kuwata K (2009) Theoretical study of the prion protein based on the fragment molecular orbital method. J Comput Chem 30:2594\u20132601","journal-title":"J Comput Chem"},{"key":"3573_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/cn300076x","volume":"3","author":"LP Jameson","year":"2012","unstructured":"Jameson LP, Smith NW, Dzyuba SV (2012) Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (a\u03b2) self-assembly. ACS Chem Neurosci 3:807\u2013819","journal-title":"ACS Chem Neurosci"},{"key":"3573_CR40","doi-asserted-by":"publisher","first-page":"7044","DOI":"10.1073\/pnas.1303510110","volume":"110","author":"YE Karapetyan","year":"2013","unstructured":"Karapetyan YE, Sferrazza GF, Zhou M, Ottenberg G, Spicer T, Chase P, Fallahi M, Hodder P, Weissmann C, Lasm\u00e9zas CI (2013) Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci U S A 110:7044","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3573_CR41","doi-asserted-by":"crossref","unstructured":"Kimura T, Sako T, Siqin, Hosokawa-Muto J, Cui YL, Wada Y, Kataoka Y, Doi H, Sakaguchi S, Suzuki M et al (2013) Synthesis of an (11) c-labeled antiprion gn8 derivative and evaluation of its brain uptake by positron emission tomography. ChemMedChem 8:1035\u20131039","DOI":"10.1002\/cmdc.201300167"},{"key":"3573_CR42","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1471-4159.2006.03889.x","volume":"98","author":"R Klingenstein","year":"2006","unstructured":"Klingenstein R, L\u00f6ber S, Kujala P, Godsave S, Leliveld SR, Gmeiner P, Peters PJ, Korth C (2006) Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 98:748\u2013759","journal-title":"J Neurochem"},{"key":"3573_CR43","doi-asserted-by":"publisher","first-page":"9836","DOI":"10.1073\/pnas.161274798","volume":"98","author":"C Korth","year":"2001","unstructured":"Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98:9836\u20139841","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3573_CR44","doi-asserted-by":"crossref","unstructured":"K\u00fcbler E, Oesch B, Raeber AJ (2003) Diagnosis of prion diseases. Br Med Bull 66:267\u2013279","DOI":"10.1093\/bmb\/66.1.267"},{"key":"3573_CR45","doi-asserted-by":"publisher","first-page":"12277","DOI":"10.1021\/bi026129y","volume":"41","author":"K Kuwata","year":"2002","unstructured":"Kuwata K, Li H, Yamada H, Legname G, Prusiner SB, Akasaka K, James TL (2002) Locally disordered conformer of the hamster prion protein: a crucial intermediate to PRPSC? Biochemistry 41:12277\u201312283","journal-title":"Biochemistry"},{"key":"3573_CR46","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.1073\/pnas.0702671104","volume":"104","author":"K Kuwata","year":"2007","unstructured":"Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK, Kimura K, Kawasaki M, Takakura Y et al (2007) Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A 104:11921\u201311926","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3573_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/19336896.2018.1525254","volume":"12","author":"CL Ladner-Keay","year":"2018","unstructured":"Ladner-Keay CL, Ross L, Perez-Pineiro R, Zhang L, Bjorndahl TC, Cashman N, Wishart DS (2018) A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds. Prion 12:280\u2013300","journal-title":"Prion"},{"key":"3573_CR48","doi-asserted-by":"crossref","unstructured":"Legname G (2017) Elucidating the function of the prion protein. PLoS Pathog 13:e1006458","DOI":"10.1371\/journal.ppat.1006458"},{"key":"3573_CR49","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.3390\/ijms22042196","volume":"22","author":"B Li","year":"2021","unstructured":"Li B, Chen M, Zhu C (2021) Neuroinflammation in prion disease. Int J Mol Sci 22:2196","journal-title":"Int J Mol Sci"},{"key":"3573_CR50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/ml300472n","volume":"4","author":"Z Li","year":"2013","unstructured":"Li Z, Gever J, Rao S, Widjaja K, Prusiner SB, Silber BM (2013a) Discovery and preliminary SAR of arylpiperazines as novel, brainpenetrant antiprion compounds. ACS Med Chem Lett 4:397\u2013401","journal-title":"ACS Med Chem Lett"},{"key":"3573_CR51","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1021\/ml300454k","volume":"4","author":"Z Li","year":"2013","unstructured":"Li Z, Rao S, Gever JR, Widjaja K, Prusiner SB, Silber BM (2013b) Optimization of arylamides as novel, potent and brain-penetrant antiprion lead compounds. ACS Med Chem Lett 4:647\u2013650","journal-title":"ACS Med Chem Lett"},{"key":"3573_CR52","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/molecules25061375","volume":"25","author":"X Lin","year":"2020","unstructured":"Lin X, Li X (2020) A review on applications of computational methods in drug screening and design. Molecules 25:1375","journal-title":"Molecules"},{"key":"3573_CR53","doi-asserted-by":"crossref","unstructured":"Marrone A, Re N, Storchi L (2016) The effects of Ca2+ concentration and e200k mutation on the aggregation propensity of prpc: A computational study. PLoS One 11:e0168039","DOI":"10.1371\/journal.pone.0168039"},{"key":"3573_CR54","first-page":"1345","volume":"126","author":"L Marzo","year":"2013","unstructured":"Marzo L, Marijanovic Z, Browman D, Chamoun Z, Caputo A, Zurzolo C (2013) 4-Hydroxytamoxifen leads to PRPSC clearance by conveying both PRPC and PRPSC to lysosomes independently of autophagy. J Cell Sci 126:1345\u20131354","journal-title":"J Cell Sci"},{"key":"3573_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.nano.2014.03.015","volume":"10","author":"M Mizrahi","year":"2014","unstructured":"Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, Fainstein N, Ovadia H, Ben-Hur T, Magdassi S et al (2014) Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic cjd. Nanomedicine 10:1353\u20131363","journal-title":"Nanomedicine"},{"key":"3573_CR56","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/17460441.2019.1637851","volume":"14","author":"F Moda","year":"2019","unstructured":"Moda F, Bolognesi ML, Legname G (2019) Novel screening approaches for human prion diseases drug discovery. Expert Opin Drug Discov 14:983\u2013993","journal-title":"Expert Opin Drug Discov"},{"key":"3573_CR57","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.2174\/0929867326666190927121744","volume":"27","author":"C Mustazza","year":"2020","unstructured":"Mustazza C, Sbriccoli M, Minosi P, Raggi C (2020) Small molecules with anti-prion activity. Curr Med Chem 27:5446\u20135479","journal-title":"Curr Med Chem"},{"key":"3573_CR58","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1021\/cn5001588","volume":"5","author":"PH Nguyen","year":"2014","unstructured":"Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, Oumata N, Bourguignon JJ, Sanyal S, Beringue V et al (2014) Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost \u03b12-adrenergic receptor agonistic activity. ACS Chem Neurosci 5:1075\u20131082","journal-title":"ACS Chem Neurosci"},{"key":"3573_CR59","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.freeradbiomed.2008.07.009","volume":"45","author":"R Pamplona","year":"2008","unstructured":"Pamplona R, Naudi A, Gavin R, Pastrana MA, Sajnani G, Ilieva EV, Del Rio JA, Portero-Otin M, Ferrer I, Requena JR (2008) Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 45:1159\u20131166","journal-title":"Free Radic Biol Med"},{"key":"3573_CR60","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.90.23.10962","volume":"90","author":"KM Pan","year":"1993","unstructured":"Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 90:10962\u201310966","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3573_CR61","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.mcn.2008.10.008","volume":"40","author":"M Pera","year":"2009","unstructured":"Pera M, Mart\u00ednez-Otero A, Colombo L, Salmona M, Ruiz-Molina D, Badia A, Clos MV (2009) Acetylcholinesterase as an amyloid enhancing factor in prp82-146 aggregation process. Mol Cell Neurosci 40:217\u2013224","journal-title":"Mol Cell Neurosci"},{"key":"3573_CR62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbrc.2006.04.187","volume":"346","author":"M Pera","year":"2006","unstructured":"Pera M, Rom\u00e1n S, Ratia M, Camps P, Mu\u00f1oz-Torrero D, Colombo L, Manzoni C, Salmona M, Badia A, Clos MV (2006) Acetylcholinesterase triggers the aggregation of PRP 106\u2013126. Biochem Biophys Res Commun 346:89\u201394","journal-title":"Biochem Biophys Res Commun"},{"key":"3573_CR63","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2147\/DDDT.S49763","volume":"7","author":"V Prachayasittikul","year":"2013","unstructured":"Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V (2013) 8-hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther 7:1157\u20131178","journal-title":"Drug Des Devel Ther"},{"key":"3573_CR64","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1126\/science.6801762","volume":"216","author":"SB Prusiner","year":"1982","unstructured":"Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136\u2013144","journal-title":"Science"},{"key":"3573_CR65","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","volume":"344","author":"SB Prusiner","year":"2001","unstructured":"Prusiner SB (2001) Shattuck lecture\u2013neurodegenerative diseases and prions. N Engl J Med 344:1516\u20131526","journal-title":"N Engl J Med"},{"key":"3573_CR66","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1089\/ars.2009.2628","volume":"12","author":"N Singh","year":"2010","unstructured":"Singh N, Singh A, Das D, Mohan ML (2010) Redox control of prion and disease pathogenesis. Antioxid Redox Signal 12:1271\u20131294","journal-title":"Antioxid Redox Signal"},{"key":"3573_CR67","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","volume":"21","author":"C Soto","year":"2018","unstructured":"Soto C, Pritzkow S (2018) Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci 21:1332\u20131340","journal-title":"Nat Neurosci"},{"key":"3573_CR68","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s42003-020-01585-x","volume":"4","author":"G Spagnolli","year":"2021","unstructured":"Spagnolli G, Massignan T, Astolfi A, Biggi S, Rigoli M, Brunelli P, Libergoli M, Ianeselli A, Orioli S, Boldrini A et al (2021) Pharmacological inactivation of the prion protein by targeting a folding intermediate. Commun Biol 4:62","journal-title":"Commun Biol"},{"key":"3573_CR69","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1021\/ml3003605","volume":"4","author":"M Staderini","year":"2013","unstructured":"Staderini M, Aulic S, Bartolini M, Tran HN, Gonzalez-Ruiz V, Perez DI, Cabezas N, Martinez A, Martin MA, Andrisano V et al (2013a) A fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer\u2019s and prion diseases. ACS Med Chem Lett 4:225\u2013229","journal-title":"ACS Med Chem Lett"},{"key":"3573_CR70","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2174\/15680266113136660176","volume":"13","author":"M Staderini","year":"2013","unstructured":"Staderini M, Legname G, Bolognesi ML, Men\u00e9ndez JC (2013b) Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. Curr Top Med Chem 13:2491\u20132503","journal-title":"Curr Top Med Chem"},{"key":"3573_CR71","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1039\/C4CS00337C","volume":"44","author":"M Staderini","year":"2015","unstructured":"Staderini M, Mart\u00edn MA, Bolognesi ML, Men\u00e9ndez JC (2015) Imaging of \u03b2-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience. Chem Soc Rev 44:1807\u20131819","journal-title":"Chem Soc Rev"},{"key":"3573_CR72","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/prot.24836","volume":"83","author":"L Storchi","year":"2015","unstructured":"Storchi L, Paciotti R, Re N, Marrone A (2015) Investigation of the molecular similarity in closely related protein systems: the PRP case study. Proteins 83:1751\u20131765","journal-title":"Proteins"},{"key":"3573_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fnins.2017.00003","volume":"11","author":"M Toni","year":"2017","unstructured":"Toni M, Massimino ML, De Mario A, Angiulli E, Spisni E (2017) Metal dyshomeostasis and their pathological role in prion and prion-like diseases: the basis for a nutritional approach. Front Neurosci 11:3","journal-title":"Front Neurosci"},{"key":"3573_CR74","doi-asserted-by":"crossref","unstructured":"Tribouillard-Tanvier D, B\u00e9ringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M (2008) Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One 3:e1981","DOI":"10.1371\/journal.pone.0001981"},{"key":"3573_CR75","doi-asserted-by":"crossref","unstructured":"T\u00f6rnqvist E, Annas A, Granath B, Jalkesten E, Cotgreave I, \u00d6berg M (2014) Strategic focus on 3r principles reveals major reductions in the use of animals in pharmaceutical toxicity testing. PLoS One 9:e101638","DOI":"10.1371\/journal.pone.0101638"},{"key":"3573_CR76","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(19)30615-2","volume":"20","author":"L Uttley","year":"2020","unstructured":"Uttley L, Carroll C, Wong R, Hilton DA, Stevenson M (2020) Creutzfeldt-jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis 20:e2\u2013e10","journal-title":"Lancet Infect Dis"},{"key":"3573_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s00401-004-0879-2","volume":"108","author":"B Van Everbroeck","year":"2004","unstructured":"Van Everbroeck B, Dobbeleir I, De Waele M, De Leenheir E, L\u00fcbke U, Martin JJ, Cras P (2004) Extracellular protein deposition correlates with glial activation and oxidative stress in Creutzfeldt-Jakob and Alzheimer\u2019s disease. Acta Neuropathol 108:194\u2013200","journal-title":"Acta Neuropathol"},{"key":"3573_CR78","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.nicl.2013.03.014","volume":"2","author":"R Vandenberghe","year":"2013","unstructured":"Vandenberghe R, Adamczuk K, Dupont P, Laere KV, Ch\u00e9telat G (2013) Amyloid pet in clinical practice: Its place in the multidimensional space of Alzheimer\u2019s disease. Neuroimage Clin 2:497\u2013511","journal-title":"Neuroimage Clin"},{"key":"3573_CR79","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00415-012-6664-6","volume":"260","author":"LH Wang","year":"2013","unstructured":"Wang LH, Bucelli RC, Patrick E, Rajderkar D, Alvarez Iii E, Lim MM, Debruin G, Sharma V, Dahiya S, Schmidt RE et al (2013) Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. J Neurol 260:498\u2013506","journal-title":"J Neurol"},{"key":"3573_CR80","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41594-020-0441-5","volume":"27","author":"LQ Wang","year":"2020","unstructured":"Wang LQ, Zhao K, Yuan HY, Wang Q, Guan Z, Tao J, Li XN, Sun Y, Yi CW, Chen J et al (2020) Cryo-em structure of an amyloid fibril formed by full-length human prion protein. Nat Struct Mol Biol 27:598\u2013602","journal-title":"Nat Struct Mol Biol"},{"key":"3573_CR81","doi-asserted-by":"crossref","unstructured":"Wang LQ, Zhao K, Yuan HY, Li XN, Dang HB, Ma Y, Wang Q, Wang C, Sun Y, Chen J et al (2021) Genetic prion disease-related mutation e196k displays a novel amyloid fibril structure revealed by cryo-em. Sci Adv 7:eabg9676","DOI":"10.1126\/sciadv.abg9676"},{"key":"3573_CR82","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-017-1790-y","volume":"135","author":"JC Watts","year":"2018","unstructured":"Watts JC, Bourkas MEC, Arshad H (2018) The function of the cellular prion protein in health and disease. Acta Neuropathol 135:159\u2013178","journal-title":"Acta Neuropathol"},{"key":"3573_CR83","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bbadis.2007.02.011","volume":"1772","author":"L Westergard","year":"2007","unstructured":"Westergard L, Christensen HM, Harris DA (2007) The cellular prion protein (prp(c)): its physiological function and role in disease. Biochim Biophys Acta 1772:629\u2013644","journal-title":"Biochim Biophys Acta"},{"key":"3573_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-021-02311-5","volume":"142","author":"AL Woerman","year":"2021","unstructured":"Woerman AL (2021) Strain diversity in neurodegenerative disease: an argument for a personalized medicine approach to diagnosis and treatment. Acta Neuropathol 142:1\u20133","journal-title":"Acta Neuropathol"},{"key":"3573_CR85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12915-017-0375-5","volume":"15","author":"MA Wulf","year":"2017","unstructured":"Wulf MA, Senatore A, Aguzzi A (2017) The biological function of the cellular prion protein: an update. BMC Biol 15:34","journal-title":"BMC Biol"},{"key":"3573_CR86","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41551-019-0349-8","volume":"3","author":"K Yamaguchi","year":"2019","unstructured":"Yamaguchi K, Kamatari YO, Ono F, Shibata H, Fuse T, Elhelaly AE, Fukuoka M, Kimura T, Hosokawa-Muto J, Ishikawa T et al (2019) A designer molecular chaperone against transmissible spongiform encephalopathy slows disease progression in mice and macaques. Nat Biomed Eng 3:206\u2013219","journal-title":"Nat Biomed Eng"},{"key":"3573_CR87","doi-asserted-by":"publisher","first-page":"12853","DOI":"10.1021\/jp905572w","volume":"113","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Kuwata K (2009) Regulating the conformation of prion protein through ligand binding. J Phys Chem B 113:12853\u201312856","journal-title":"J Phys Chem B"},{"key":"3573_CR88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/19336896.2020.1714372","volume":"14","author":"S Yamashita","year":"2020","unstructured":"Yamashita S, Honda R, Fukuoka M, Kimura T, Hosokawa-Muto J, Kuwata K (2020) Discovery of a multipotent chaperone, 1-(2,6-difluorobenzylamino)-3-(1,2,3,4-tetrahydrocarbazol-9-yl)-propan-2-ol with the inhibitory effects on the proliferation of prion, cancer as well as influenza virus. Prion 14:42\u201346","journal-title":"Prion"},{"key":"3573_CR89","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.expneurol.2006.03.025","volume":"201","author":"SW Yun","year":"2006","unstructured":"Yun SW, Gerlach M, Riederer P, Klein MA (2006) Oxidative stress in the brain at early preclinical stages of mouse scrapie. Exp Neurol 201:90\u201398","journal-title":"Exp Neurol"},{"key":"3573_CR90","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ejmech.2016.10.064","volume":"127","author":"L Zaccagnini","year":"2017","unstructured":"Zaccagnini L, Brogi S, Brindisi M, Gemma S, Chemi G, Legname G, Campiani G, Butini S (2017) Identification of novel fluorescent probes preventing prp. Eur J Med Chem 127:859\u2013873","journal-title":"Eur J Med Chem"},{"key":"3573_CR91","doi-asserted-by":"crossref","unstructured":"Zaccagnini L, Rossetti G, Tran TH, Salzano G, Gandini A, Colini Baldeschi A, Bolognesi ML, Carloni P, Legname G (2020) In silico\/in vitro screening and hit evaluation identified new phenothiazine anti-prion derivatives. Eur J Med Chem 196:112295","DOI":"10.1016\/j.ejmech.2020.112295"},{"key":"3573_CR92","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1073\/pnas.97.1.145","volume":"97","author":"R Zahn","year":"2000","unstructured":"Zahn R, Liu A, L\u00fchrs T, Riek R, von Schroetter C, L\u00f3pez Garc\u00eda F, Billeter M, Calzolai L, Wider G, W\u00fcthrich K (2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 97:145\u2013150","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3573_CR93","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1021\/acschemneuro.0c00218","volume":"11","author":"DH Zhou","year":"2020","unstructured":"Zhou DH, Wang J, Xiao K, Wu YZ, Maimaitiming A, Hu C, Gao LP, Chen J, Gao C, Chen C et al (2020) Stilbene compounds inhibit the replications of various strains of prions in the levels of cell culture, PMCA, and RT-QuIC possibly via molecular binding. ACS Chem Neurosci 11:2117\u20132128","journal-title":"ACS Chem Neurosci"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-021-03573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00441-021-03573-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-021-03573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T17:05:33Z","timestamp":1682355933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00441-021-03573-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1007\/s00441-021-03573-x","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}